Rocket Pharmaceuticals Stock Forum

Several highly anticipated PDUFA decisions are approaching..👇
Abeona Therapeutics ($Abeona Therapeutics(ABEO.US)$ )
Asset: Pz-cel (prademagene zamikeracel)
PDUFA Date: May 25, 2024
Indication: Recessive dystrophic epidermolysis bullosa (RDEB)
Technology: Autologous cell therapy, treatment uses gene transfer to deliver COL7A1 genes into an RDEB patient’s own skin cells then transplanting them back to the patient.
Rocket Pharmaceuticals ($Rocket Pharmaceuticals(RCKT.US)$ )...

$Rocket Pharmaceuticals(RCKT.US)$ 🐂31.49

$Rocket Pharmaceuticals(RCKT.US)$ looks like time to get in again in rocket ! probability of going maximum high is 99.99%

$Rocket Pharmaceuticals(RCKT.US)$ oww still moving after i sold awaiting pull back

Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR S&P Biotech ETF(XBI.US)$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the$S&P 500 Index(.SPX.US)$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...

$Rocket Pharmaceuticals(RCKT.US)$ sold my rocket trying practicing not to be greedy here 😎 👍traders

$Rocket Pharmaceuticals(RCKT.US)$ bought few here 📈

$Rocket Pharmaceuticals(RCKT.US)$ • Rocket Pharmaceuticals (NASDAQ:RCKT) announced Monday that the U.S. FDA accepted its marketing application for gene therapy RP-L201 under priority review for severe Leukocyte Adhesion Deficiency-I (LAD-I), a rare immune disorder in children.
• The Biologics License Application (BLA) for cell therapy is backedby data from the company's global Phase 1/2 study for RP-L201, which reached all primary and secondary endpoints, indicating a 100% overall survival...